Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00621244 · OUTCOME

Maximum Plasma Concentration of Panobinostat After the First Dose in Arms 1 and 2

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies · Source last updated 2021-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
Day 1

Analysis population: Pharmacokinetic set: Pharmacokinetic population consisted of all patients who provided at least one postdose PK plasma sample.

Groups in this outcome

20 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

30 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

40 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

45 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

60 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

80 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
20 mg9
30 mg18
40 mg24
45 mg15
60 mg53
80 mg18

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
20 mg19.511.84Not reportedNot reportedNot reported
30 mg39.827.51Not reportedNot reportedNot reported
40 mg5834.25Not reportedNot reportedNot reported
45 mg5428.38Not reportedNot reportedNot reported
60 mg66.946.55Not reportedNot reportedNot reported
80 mg63.536.6Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        11.84
        value
        19.5
      2. group Id
        OG001
        spread
        27.51
        value
        39.8
      3. group Id
        OG002
        spread
        34.25
        value
        58
      4. group Id
        OG003
        spread
        28.38
        value
        54
      5. group Id
        OG004
        spread
        46.55
        value
        66.9
      6. group Id
        OG005
        spread
        36.6
        value
        63.5
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      18
    3. group Id
      OG002
      value
      24
    4. group Id
      OG003
      value
      15
    5. group Id
      OG004
      value
      53
    6. group Id
      OG005
      value
      18
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG000
    title
    20 mg
  2. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG001
    title
    30 mg
  3. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG002
    title
    40 mg
  4. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG003
    title
    45 mg
  5. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG004
    title
    60 mg
  6. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG005
    title
    80 mg
param Type
MEAN
population Description
Pharmacokinetic set: Pharmacokinetic population consisted of all patients who provided at least one postdose PK plasma sample.
reporting Status
POSTED
time Frame
Day 1
title
Maximum Plasma Concentration of Panobinostat After the First Dose in Arms 1 and 2
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice